JP2020512361A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512361A5
JP2020512361A5 JP2019553224A JP2019553224A JP2020512361A5 JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5 JP 2019553224 A JP2019553224 A JP 2019553224A JP 2019553224 A JP2019553224 A JP 2019553224A JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5
Authority
JP
Japan
Prior art keywords
antibody
complex
molecule
combination
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512361A (ja
Filing date
Publication date
Priority claimed from US15/937,493 external-priority patent/US20190048055A1/en
Application filed filed Critical
Publication of JP2020512361A publication Critical patent/JP2020512361A/ja
Publication of JP2020512361A5 publication Critical patent/JP2020512361A5/ja
Pending legal-status Critical Current

Links

JP2019553224A 2017-03-31 2018-03-30 癌治療のために抗cd38抗体と併用したalt−803 Pending JP2020512361A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480339P 2017-03-31 2017-03-31
US62/480,339 2017-03-31
US15/937,493 US20190048055A1 (en) 2017-03-31 2018-03-27 Alt-803 in combination with anti-cd38 antibody for cancer therapies
US15/937,493 2018-03-27
PCT/US2018/025366 WO2018183821A1 (en) 2017-03-31 2018-03-30 Alt-803 in combination with anti-cd38 antibody for cancer therapies

Publications (2)

Publication Number Publication Date
JP2020512361A JP2020512361A (ja) 2020-04-23
JP2020512361A5 true JP2020512361A5 (cg-RX-API-DMAC7.html) 2021-04-30

Family

ID=63678335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553224A Pending JP2020512361A (ja) 2017-03-31 2018-03-30 癌治療のために抗cd38抗体と併用したalt−803

Country Status (9)

Country Link
US (1) US20190048055A1 (cg-RX-API-DMAC7.html)
EP (1) EP3601363B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512361A (cg-RX-API-DMAC7.html)
KR (1) KR102748188B1 (cg-RX-API-DMAC7.html)
CN (1) CN110494449B (cg-RX-API-DMAC7.html)
AU (1) AU2018243550B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058427C (cg-RX-API-DMAC7.html)
TW (1) TW201841651A (cg-RX-API-DMAC7.html)
WO (1) WO2018183821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464352B1 (en) 2016-05-27 2021-03-24 Altor BioScience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102625293B1 (ko) 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
KR102692667B1 (ko) 2020-11-17 2024-08-06 고려대학교 산학협력단 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도
CN113293191A (zh) * 2021-05-28 2021-08-24 山东大学齐鲁医院 Gfp转染肿瘤细胞的方法在检测肿瘤相关巨噬细胞吞噬功能中的应用
EP4376869A1 (en) * 2021-07-28 2024-06-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023178253A2 (en) * 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
GB202315149D0 (en) 2023-10-03 2023-11-15 Celleron Therapeutics Ltd Combination therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507A (en) 1851-11-11 petess
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7213961B2 (en) 2003-07-11 2007-05-08 Hubbell Incorporated Low voltage luminaire assembly
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JP2018529753A (ja) * 2015-10-06 2018-10-11 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物

Similar Documents

Publication Publication Date Title
DK2944323T3 (en) Means for the treatment of tumors, their use and their method
JP2019516748A5 (cg-RX-API-DMAC7.html)
JP2021525735A5 (cg-RX-API-DMAC7.html)
WO2014142220A1 (ja) 抗腫瘍剤
JP2021535149A5 (cg-RX-API-DMAC7.html)
JP2015517511A5 (cg-RX-API-DMAC7.html)
US20200377596A1 (en) Dosing of bispecific t cell engager
EP3972609B1 (en) Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
JP2020510011A5 (cg-RX-API-DMAC7.html)
JP2013543869A5 (cg-RX-API-DMAC7.html)
US9687472B2 (en) Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress
CN102935228B (zh) 用于肿瘤治疗的试剂、其用途及方法
EP4319815A1 (en) Dosing of bispecific t cell engager
Sylvan et al. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
JP2016104703A (ja) 抗腫瘍剤
US20170100433A1 (en) Modified natural killer cells having anti-fugetactic properties and uses thereof
JP2023536596A5 (cg-RX-API-DMAC7.html)
Chen et al. IMMU-23. Eliminating Monocyte Chemoattraction Invokes Compensatory Neutrophil Influx and Proneural to Mesenchymal Transition in Glioblastoma
Zhang et al. PF299 EARLY RESPONSE OBSERVATION OF PEDIATRIC PATIENTS WITH BURKITT'S LYMPHOMA TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELLS
Sun et al. Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma
Zent Monoclonal antibody therapy in chronic lymphocytic leukemia
Khot et al. A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM)
TW202517679A (zh) 以抗ilt2抗體治療癌症
Karatrasoglou et al. Oncology news/literature Review/July-December 2019
JP2022028682A (ja) 抗fugetactic特性を有する改変されたT細胞およびその使用